Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/18/2013

ing OMS103HP to vehicle control in 344 patients undergoing arthroscopic partial meniscectomy surgery.  The pre-specified primary endpoint was the Symptoms Subscale of the KOOS – a patient-reported measure that is comprised of questions about knee swelling, clicking, catching and stiffness. In addition, pain measured in the early postoperative period was a pre-specified secondary endpoint. Although the Symptoms Subscale of the KOOS did not reach statistical significance, OMS103HP achieved statistically significant (p=0.0003) reduction of postoperative pain. The pain reduction data were similar in magnitude to those in the Phase 2 clinical trial. Omeros expects to conduct two concurrent Phase 3 clinical trials with reduction of early postoperative pain as the pre-specified primary endpoint and to begin enrolling patients in the first of these two planned trials in the first half of 2013. Each of these two additional Phase 3 clinical trials will enroll substantially fewer subjects than were required for the first Phase 3 trial assessing KOOS as the primary endpoint given the increased statistical power associated with reduction in early postoperative pain shown in the Phase 2 and first Phase 3 meniscectomy clinical trials.

About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Be
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
2. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
3. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
4. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
5. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
6. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
7. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
8. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
9. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
10. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
11. Celsion Corporation Announces $15 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation ... its comprehensive line of analytical laboratory equipment. With optimized features, such as PTFE-coated ... a chemically resistant and maintenance-free solution for a broad range of vacuum filtration ...
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
(Date:7/30/2015)... AACC welcomed thousands of medical professionals ... Meeting & Clinical Lab Expo in ... showcased revolutionary advancements in clinical testing technology and ... to diagnose patients quickly and accurately and make ... As of Wednesday, July 29, more than ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research ... on the current state of the global Propanol market with a focus on the ... Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3
... 19, 2012  Nautilus Neurosciences announced today that their ... subsidiary of Stellar Pharmaceuticals, was granted a Notice ... CAMBIA® (diclofenac potassium for oral solution) in the ... in adults. CAMBIA® is expected to be launched ...
... Cancer Research Centre (CNIO) routinely runs such tests on samples ... just the first step towards a truly personalised medicine. And ... in each organism at a molecular scale: the genes that ... antibodies circulating through the bloodstream; and the length of the ...
... of yoghurt have a note telling you that the product ... the spatial arrangement of their atoms. The two"isomers", L(+) and ... light to the right or left respectively. Of course the ... is not confined to solutions of yoghurt. Light interacts in ...
Cached Biology Technology:Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine 2Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine 3CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3Designer lights from the physics lab 2
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... malaria parasites form mutations that make them stubbornly resistant ... new treatments for a disease that afflicts more than ... disease models using yeast and successfully introduced five mutations ... The study, featured as the cover story of the ...
... consequences for humans and most animals but not Australia's ... The University of Queensland has found that unlike most ... starvation, the green-striped burrowing frog is able to absorb ... food, than frogs that had eaten regularly. , "They ...
... community over the evolution of the Great White shark, and ... Wright State University Lake Campus, is right in the middle ... one of the most feared predators of the sea, evolved ... rests with the mako shark. , "Most scientists would probably ...
Cached Biology News:Molecular models advance the fight against malaria 2A frog's life is food for thought 2A frog's life is food for thought 3Great White shark evolution debate involves WSU Lake Campus geology professor 2
Agarose, Biotechnology grade, 500g...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... The c-Jun proto-oncogene was first identified as ... v-jun oncogene. Jun B and Jun D have ... in their C-terminal regions, which are involved in ... which are involved in transcriptional activation, diverge. ...
...
Biology Products: